nSMase3: Novel neutral Sphingomyelinase and its use for diagnostics andtherapy with focus on heart muscle diseases and male fert
A novel human TNF-responsible neutral phingomyelinase enzyme (nSMase3) has been identified. Furthermore, the invention relates to the use of nSMase3 as pharmaceutical and diagnostic target
and to appropriate test systems. The human enzyme was identified by screening database sequences with up to now unknow n function w ith a short sequence derived from a bovine neutral sphingomyelinase. The identified nSMase3 shows no significant homologies to the well-know n human neutral sphingomyelinases type 1 and type 2.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
